In addition, we show that MDA modification of HDL results in reduced ability to activate PON1, which may be relevant to FH patients who have increased plasma MDA-HDL adducts that likely contribute to their decreased PON1 activity and HDL dysfunction. This evidence concerns the gene PON1 and familial hyperaldosteronism.